An initial trial suggests that a new drug, originally developed for use with cancer patients, could improve the survival of patients with acute respiratory distress syndrome (ARDS). The patients in the trial were all critically unwell with ARDS, caused by severe Covid-19, and the invariant natural killer T (iNKT) cell therapy triggered an immune response in these individuals.